Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer
The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.
Neoplasms
DRUG: SSR97225
Maximal tolerated dose (MTD) and dose limiting toxicity (DLT), Study period
Pharmacokinetic profile, antitumor activity in patients with measurable disease, effect of drug on CYP3A4 activity, Study period
The purpose of this study is to determine the maximally tolerated dose and the dose limiting toxicity of this antimitotic, tubulin binding investigational drug for those patients who have failed standard anticancer treatments.